PRESS RELEASE

    Leading BPO Company to provide high-end analytics and revenue
                           cycle management

NEW YORK--(BUSINESS WIRE)--Sept. 15, 2008--WNS (Holdings) Limited (NYSE: WNS) a leading provider of global business process outsourcing (BPO) services, today announced a multi-year contract to provide healthcare revenue cycle management services to EBI LLC (a Biomet Inc. subsidiary, d/b/a Biomet Trauma and Biomet Spine). Under the five-year agreement, WNS will deliver service level improvements utilizing high-end analytics to optimize collections and order processes.

Jim Bechtold, Senior Vice President Reimbursement and Government Affairs of Biomet Trauma and Biomet Spine commented, "We selected WNS because they understand operating requirements in the healthcare sector. They bring a winning combination of experience and commitment to excellence. During our rigorous selection process, WNS showed us their flexibility and significant analytics capabilities by developing a fine-tuned customized business solution. Leveraging WNS' resources and Biomet's reimbursement expertise, this contract offers us significant quality improvement opportunities for our healthcare revenue cycle."

"Business processes in the healthcare industry are unique. This agreement gives WNS the opportunity to again deploy our company's knowledge and experience in insurance claims and collection processes in this industry," said Neeraj Bhargava, CEO of WNS Global Services. "We are pleased to partner with Biomet Trauma and Biomet Spine to help them achieve higher levels of operational efficiency by streamlining processes critical to revenue cycle management."

WNS offers a full range of services to U.S. healthcare clients in the payer, provider, medical device and pharmaceutical sectors. The company delivers a comprehensive suite of customized reimbursement solutions to leading global companies.

About WNS

WNS is a leading global business process outsourcing company. Deep industry and business process knowledge, a partnership approach, comprehensive service offering and a proven track record enable WNS to deliver business value to some of the leading companies in the world. WNS is passionate about building a market-leading company valued by our clients, employees, business partners, investors and communities. For more information, visit www.wnsgs.com.

About Biomet, Inc.

Biomet, Inc. and its subsidiaries design, manufacture, and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet's product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 70 countries.

Safe Harbor Statement under the provisions of the United States Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements, as defined in the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. . These forward-looking statements include statements relating to Biomet's service requirements and the services to be provided by WNS under the contract with Biomet, the benefits of such services, and the projected revenue expected to be generated over the course of the contract with Biomet. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those that may be projected by these forward looking statements. These risks and uncertainties include but are not limited to technological innovation; telecommunications or technology disruptions; future regulatory actions and conditions in our operating areas; our dependence on a limited number of clients in a limited number of industries; our ability to attract and retain clients; our ability to expand our business or effectively manage growth; our ability to hire and retain enough sufficiently trained employees to support our operations; negative public reaction in the US or the UK to offshore outsourcing; regulatory, legislative and judicial developments; increasing competition in the business process outsourcing industry; political or economic instability in India, Sri Lanka and Jersey; worldwide economic and business conditions, including a slowdown in the U.S. and Indian economies and in the sectors in which our clients are based and a slowdown in the BPO and IT sectors world-wide; our ability to successfully consummate strategic acquisitions, as well as other risks detailed in our reports filed with the U.S. Securities and Exchange Commission. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's current analysis of future events. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    CONTACT: WNS (Holdings) Limited
             Investors:
             Alan Katz, +1 212-599-6960 ext. 241
             VP -- Investor Relations
             ir@wnsgs.com
             or
             Gutenberg Communications
             Media:
             U.S.
             Aquin Dennison, + 1 917-664-7235
             aquin@gutenbergpr.com
             or
             India
             Pranav Kumar, + 91 98100 77898
             pranav@gutenbergpr.com
             or
             UK
             Shalini Siromani, +44 203 008 5231
             shalini@gutenbergpr.com

    SOURCE: WNS (Holdings) Limited